30th April 2019
Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester and Cancer Research UK. The project will explore the potential of aptamers as […]
30th April 2019
31st March 2019
Novel ELISA like assay for small molecules
Moxifloxacin aptamer and intellectual property (IP) availability
Interesting applications in biologic and biosimilar analysis and cell imaging
With lots of exciting new data ongoing for multiple applications in the commercial and academic space, Aptamer Group would like to share with you information that may be […]
17th January 2019
Aptamer Group announces collaboration with AstraZeneca
Cancer Biomarker Capture and Elution by Cell Specific Aptamers
Laboratory and Office expansion
Interesting applications in glioblastoma and hepatocellular carcinoma (HCC) biomarker aptamers
With lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to share with […]
7th January 2019
Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs).
19th December 2018
Aptamer Group data on selective cell based biomarker aptamers
The year in review, from new product launches to company accolades
Interesting applications in international diagnostics and small molecule lateral flow assays
Novel Solutions – Biomarkers
Aptamers specific to the same cell type at different stages within a disease cycle
No biomarker abundance restriction
14th December 2018
We are proud to announce that we have negotiated an agreement with York Science Park to expand our premises.
The addition of two further laboratories and two offices to our existing space of five labs and four offices will allow us to continue our growth. The additional space has allowed us to set up […]
29th November 2018.
Aptamer Group data on selective bind and elution reusability of aptamer purification columns
Small molecule analysis webinar with Pall ForteBio BLI platform
Our CEO Today United Kingdom award
Interesting applications in antibiotic biosensors and ELISA antibody/aptamer pairs
Novel Solutions – Purification
Reproducibility of aptamers that bind and release under defined conditions
3rd December 2018
Aptamer Group is proud to receive the CEO Today Magazine United Kingdom Awards for distinguished performance by our CEO and Founder Arron Tolley.
The award recognises, identifies and honours the most respected companies and their C-level executives operating within the United Kingdom today. Researchers at CEO Today determine the eligibility of the CEO/Executive based […]
10th October 2018
Our Chief Technical Officer, David Bunka, gave a talk on how aptamers can be used in microbiology at The Microbiology Show in Derby.
The Microbiology Show brings together the technology, equipment, consultancy and services associated with the field of microbiology together in one event. There were a series of keynote presentations from thought leaders in […]
19th October 2018.
This month data on our new improved delivery standard, webinar with Pall ForteBio, and interesting applications in targeted treatment and environmental detection of small molecules.
Following on from a successful Series A investment and lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to […]